ARTICLE | Company News
Aurigene, Curis deal
October 17, 2016 7:00 AM UTC
Curis exercised an option from Aurigene to license exclusive, worldwide rights outside India and Russia to preclinical oncology candidate CA-327 -- an oral small molecule antagonist of PD-L1 and T cell immunoglobulin and mucin domain 3 (TIM3; HAVCR2). ...